Population Pharmacokinetics of Acyclovir in Children and Young People with Malignancy after Administration of Intravenous Acyclovir or Oral Valacyclovir

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Antimicrobial Agents and Chemotherapy

• Publication date

  2009-05-04

• Fields of study

  Medicine

• Identifiers
  DOI 10.1128/AAC.01138-08PMID 19414579PMCID PMC2704705
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• HPLC-fluorescence assay for acyclovir in children.

  2008cited by this paper
• Prevention of VZV infection in immunosuppressed patients using antiviral agents.

  2006cited by this paper
• Evaluation of Pharmacokinetic Interactions After Oral Administration of Mycophenolate Mofetil and Valaciclovir or Aciclovir to Healthy Subjects

  2004influential reference
• Population Pharmacokinetics III: Design, Analysis, and Application of Population Pharmacokinetic Studies

  2004cited by this paper
• Model Appropriateness and Population Pharmacokinetic Modeling

  2003cited by this paper
• Pharmacokinetics and Safety of Valaciclovir in Children with Epstein-Barr Virus Illness

  2002cited by this paper
• An investigation of the steady-state pharmacokinetics of oral valacyclovir in immunocompromised children.

  2002cited by this paper
• Comparison of stepwise covariate model building strategies in population pharmacokinetic-pharmacodynamic analysis

  2002cited by this paper
• Pharmacokinetics of acyclovir in immunocompromized children with leukopenia and mucositis after chemotherapy: can intravenous acyclovir be substituted by oral valacyclovir?

  2002cited by this paper
• Assessment of Actual Significance Levels for Covariate Effects in NONMEM

  2001influential reference
• Pharmacokinetics of Oral Acyclovir in Neonates and in Infants: a Population Analysis

  2001influential reference
• A double-blind, randomized study assessing the equivalence of valacyclovir 1000 mg once daily versus 500 mg twice daily in the episodic treatment of recurrent genital herpes. Genival Study Group.

  1999cited by this paper
• A double-blind, randomized study assessing the equivalence of valacyclovir 1000 mg once daily versus 500 mg twice daily in the episodic treatment of recurrent genital herpes

  1999cited by this paper
• A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models.

  1999cited by this paper
• 1 User’s guide

  1998cited by this paper
• Clinical Pharmacokinetics of Mycophenolate Mofetil

  1998cited by this paper
• Valaciclovir for the suppression of recurrent genital herpes simplex virus infection: a large-scale dose range-finding study. International Valaciclovir HSV Study Group.

  1998cited by this paper
• Stability and Performance of a Population Pharmacokinetic Model

  1997cited by this paper
• A Size Standard for Pharmacokinetics

  1996cited by this paper
• A large-scale, placebo-controlled, dose-ranging trial of peroral valaciclovir for episodic treatment of recurrent herpes genitalis. Valaciclovir HSV Study Group.

  1996cited by this paper
• Valaciclovir

  1996cited by this paper
• Population Pharmacokinetic Modeling: The Importance of Informative Graphics

  1995cited by this paper
• Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans

  1995cited by this paper
• Infectious Morbidity Associated with Long-Term Use of Venous Access Devices in Patients with Cancer

  1993cited by this paper
• The importance of modeling interoccasion variability in population pharmacokinetic analyses

  1993cited by this paper
• Pharmacokinetics of the acyclovir pro‐drug valaciclovir after escalating single‐and multiple‐dose administration to normal volunteers

  1993cited by this paper
• Acyclovir therapy in neonates.

  1992cited by this paper
• Acyclovir therapy in neonates.

  1991cited by this paper
• Neurotoxicity of acyclovir in end stage renal disease.

  1990cited by this paper
• Acyclovir

  1989cited by this paper
• A randomized trial of oral versus intravenous acyclovir for treatment of herpes zoster in bone marrow transplant recipients. Nordic Bone Marrow Transplant Group.

  1989cited by this paper
• A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts.

  1989cited by this paper
• Excessive serum concentrations of acyclovir and neurotoxicity.

  1988cited by this paper
• Book ReviewNeuroanatomy: An atlas of structures, sections and systems

  1987cited by this paper
• Ioverdose with Acyclovir in a CAPD Patient

  1987cited by this paper
• Varicella in children with cancer: impact of antiviral therapy and prophylaxis.

  1987cited by this paper
• Simplified calculation of body-surface area.

  1987influential reference
• Simplified Calculation of Body-Surface Area

  1987cited by this paper
• Analysis of pharmacokinetic data using parametric models. III. Hypothesis tests and confidence intervals

  1986influential reference
• Evaluation of Oral Acyclovir Therapy

  1985cited by this paper
• Clinical Pharmacokinetics of Acyclovir

  1983cited by this paper
• Acyclovir prophylaxis against herpes simplex virus infection in patients with leukemia. A randomized, double-blind, placebo-controlled study.

  1983cited by this paper
• Pharmacokinetics of acyclovir after intravenous and oral administration.

  1983cited by this paper
• Overview of acyclovir pharmacokinetic disposition in adults and children.

  1982cited by this paper
• Estimation of glomerular filtration rate from plasma creatinine concentration in children.

  1976cited by this paper

• Impact of continuous hemodiafiltration on serum acyclovir concentrations in a patient with encephalopathy.

  2025cites this paper
• Revisiting Acyclovir Dosing for Adult Viral Encephalitis Using a Full Bayesian LeiCNS PBPK Modeling Approach

  2025influential citation
• Distribution of acyclovir in central nervous system compartments: a porcine pharmacokinetic model

  2025cites this paper
• Population pharmacokinetics and dose rationale for aciclovir in term and pre‐term neonates with herpes

  2024cites this paper
• Revisiting acyclovir dosing for viral encephalitis using a Bayesian PBPK modeling approach

  2024cites this paper
• PharmGKB summary: acyclovir/ganciclovir pathway

  2022cites this paper
• Shedding a Light on Acyclovir Pharmacodynamics: A Retrospective Analysis on Pharmacokinetic/Pharmacodynamic Modelling of Acyclovir for the Treatment of Varicella Zoster Virus Infection in Immunocompromised Patients: A Pilot Study

  2022cites this paper
• Population Pharmacokinetics of Intravenous Acyclovir in Oncologic Pediatric Patients

  2022cites this paper
• Antiviral Agents for the Prevention and Treatment of Herpes Simplex Virus Type-1 Infection in Clinical Oncology: A Network Meta-Analysis

  2020cites this paper
• Population Pharmacokinetics of Intravenous and Oral Acyclovir and Oral Valacyclovir in Pediatric Population To Optimize Dosing Regimens

  2020cites this paper
• Formulation of acyclovir-loaded solid lipid nanoparticles: 2. Brain targeting and pharmacokinetic study

  2019cites this paper
• 153 – Drugs for Herpesvirus Infections

  2017cites this paper
• Prospective, Controlled Study of Acyclovir Pharmacokinetics in Obese Patients

  2016cites this paper
• Age Variation when Coining Drugs as High vs Low Hepatic Extraction Ratio

  2016cites this paper
• Considering Age Variation When Coining Drugs as High versus Low Hepatic Extraction Ratio

  2016cites this paper
• Acyclovir Dosing and Acute Kidney Injury: Deviations and Direction.

  2015cites this paper
• Synthesis of hybrid polymer blend nanoparticles and incorporation into in situ gel foam spray for controlled release therapy using a versatile synthetic purine nucleoside analogue antiviral drug

  2015cites this paper
• Pharmacokinetic modelling of dialytic clearance in a case of acyclovir intoxication.

  2015cites this paper
• Development of a paediatric population pharmacokinetic model for valacyclovir from literature non-compartmental values originating from sparse studies and Bayesian priors: a simulation study

  2015cites this paper
• Pharmacokinetic/pharmacodynamic modelling approaches in paediatric infectious diseases and immunology

  2014cites this paper
• Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children Now Online

  2013cites this paper
• Aciclovir and Varicella-zoster-immunoglobulin in solid-organ transplant recipients

  2011cites this paper
• Valacyclovir: approved and off-label uses for the treatment of herpes virus infections in immunocompetent and immunocompromised adults

  2010cites this paper
• ACICLOVIR-INDUCED NEUROPSYCHIATRIC SYMPTOMS- A CLINICAL PHARMACOLOGY STUDY

  2010cites this paper
• Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and

  2009cites this paper